Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2237-2242

  Jiang, Jingting ^a,b   Xu, Ning ^b   Wu, Changping ^a   Deng, Haifeng ^a   Lu, Mingyang ^a   Li, Min ^a   Xu, Bin ^a   Wu, Jun ^a   Wang, Rongchao ^a   Xu, Jun ^a   Nilsson Ehle, Peter ^b  

^a SOOCHOW UNIVERSITY   (China)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cytokine induced killer cells; Gastric carcinoma; Immunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALLOPATHY; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL TRANSPLANTATION; CHILL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; HEADACHE; HUMAN; IMMUNITY; IN VITRO STUDY; KILLER CELL; LIFESPAN; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NAUSEA AND VOMITING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUALITY OF LIFE; STOMACH CANCER; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUCOVORIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 33745565374     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chen Z, Zheng T and Chen J: Evaluation of ten-year results of cancer prevention and treatment in Changle City with high incidence of gastric cancer. Zhonghua Zhong Liu Za Zhi 22: 311-313, 2000.
2. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
3. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F and Van Cutsem E: Gastric cancer. Crit Rev Oncol Hematol 54: 209-241, 2005.
4. Leemhuis T, Wells S, Scheffold C, Edinger M and Negrin RS: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11: 181-187, 2005.
5. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP and Wang FS: Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10: 1146-1151, 2004.
6. Rosenberg S: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75: 595-603, 1985.
7. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
8. Yun YS, Hargrove ME and Ting CC: In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 49: 4770-4774, 1989.
9. Takahashi H, Nakada T and Puisieux I: Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259: 1460-1463, 1993.
10. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
11. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49: 335-345, 2000.
12. Jiang J, Wu C and Deng H: Compare cytotoxicity of cytokine-induced killer cells with tumor infiltrating lymphocytes in vitro. Lab Med 20: 322-324, 2005.
13. Sobin LH and Wittekind C (eds.): TNM Classification of Malignant Tumours (sixth edited). UICC (International Union Against Cancer), pp. 65-68, 2002.
14. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92: 1644-1649, 2005.
15. + killer cells. Ann Hematol 74: 51-56, 1997.
16. Kologlu M, Kama NA, Reis E, Doganay M, Atli M and Dolapci M: A prognostic score for gastric cancer. Am J Surg 179: 521-526, 2000.
17. + natural killer cells. Hum Immunol 62: 1092-1098, 2001.
18. Collett D: Modelling Survival Data in Medical Research. Chapman and Hall, London, 1994.
19. Yates JW, Chalmer B and McKegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220-2224, 1980.
20. Chen L, Tian H, Chen J, He ZG, Tao SF, Lokesh G and Peng SY: Surgical management of gastric stump cancer: a report of 37 cases. J Zhejiang Univ Sci B 6: 38-42, 2005.
21. Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke H, Schleicher J, Vanhoefer U, Jehle EC, Oechsle K, Trarbach T, Boehlke I et al: Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol 16: 1326-1333, 2005.
22. Lin WL, Li DG, Chen Q and Lu HM: Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol 10: 2911-2915, 2004.
23. Abe M, Nishimura Y and Shibamoto Y: Intraoperative radiation therapy for gastric cancer. World J Surg 19: 544-547, 1995.
24. Klautke G, Foitzik T, Ludwig K, Ketterer P, Klar E and Fietkau R: Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol 180: 695-700, 2004.
25. Zuo Y, Xu M, Shen D, Lu WD and Lu JF: Postoperative intraperitoneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua Zhong Liu Za Zhi 26: 247-249, 2004.
26. Bozzetti F, Vaglini M and Deraco M: Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Tumori 84: 483-488, 1998.
27. Yu QS, Zhang FZ and Tang XR: Clinical study on early use of Chinese medicinal herbs and chemotherapy after operation of gastric cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 15: 459-461, 1995.
28. Wang GT: Treatment of operated late gastric carcinoma with prescription of strengthening the patient's resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals. Zhong Xi Yi Jie He Za Zhi 10: 712-716, 707, 1990.
29. Herberman RB: Cancer therapy by biological response modifiers. Clin Physiol Biochem 5: 238-248, 1987.
30. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C and Forman SJ: Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 157: 231-240, 1997.
31. Liu J, Hu JL, Zhang XY, Qiao TD, Chen XT, Wu KC, Ding J and Fan DM: The value of MG7 antigen in predicting cancerous change in dysplastic gastric mucosa. Int J Clin Pract 56: 169-172, 2002.
32. Ychou M, Duffour J, Kramar A, Gourgou S and Grenier J: Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers 16: 105-110, 2000.